![]() |
|
|
Vol. 287, Issue 2, 616-624, November 1998
Departments of
Pharmacology and Toxicology (J.W.P., S.M.O.) and
Anesthesiology (W.B.G.), College of Medicine, University of Arkansas
for Medical Sciences, Little Rock, Arkansas
Our purpose was to determine mechanisms and methods for significantly
increasing the renal coelimination of phencyclidine (PCP) and an
anti-PCP monoclonal antibody binding fragment (anti-PCP Fab). To
accomplish this goal, we performed a series of experiments to examine
the dose-dependence of Fab elimination, mechanisms for enhancing PCP
and Fab urinary coelimination and the antigenicity of repeated Fab
administration. The results showed that urinary elimination of PCP and
anti-PCP Fab was linear over a 30-fold range of doses. Anti-PCP Fab
serum pharmacokinetics were best described using bi- or tri-exponential
curves with a terminal elimination half-life of approximately 8 hr.
Nevertheless, under all experimental conditions the early, nonterminal
phase(s) were responsible for the majority (60%) of intact Fab
elimination, with only 40% of the Fab eliminated during the terminal
phase. These data suggest that the early rapid decline in Fab serum
concentrations was primarily due to passive filtration and excretion of
intact Fab, and not due to extravascular distribution as previously
described. In comparison of methods for enhancing renal coelimination
of Fab and PCP, systemic alkalinization produced a significant increase in Fab urinary elimination, with 69% of the Fab dose and 41% of the
PCP dose recovered intact in the urine. Finally, in studies of the
antigenicity of Fab, repeated administration of Fab produced no
significant immune response or renal impairment. Overall, these experiments suggest that careful attention to the physiological status
of the kidney during early time periods is essential for maximum
coelimination of Fab and bound chemicals.
This article has been cited by other articles:
![]() |
E. C. Peterson, E. M. Laurenzana, W. T. Atchley, H. P. Hendrickson, and S. M. Owens Development and Preclinical Testing of a High-Affinity Single-Chain Antibody against (+)-Methamphetamine J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 124 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Proksch, W. B. Gentry, and S. M. Owens The Effect of Rate of Drug Administration on the Extent and Time Course of Phencyclidine Distribution in Rat Brain, Testis, and Serum Drug Metab. Dispos., July 1, 2000; 28(7): 742 - 747. [Abstract] [Full Text] |
||||
![]() |
J. W. Proksch, W. B. Gentry, and S. M. Owens Anti-Phencyclidine Monoclonal Antibodies Provide Long-Term Reductions in Brain Phencyclidine Concentrations during Chronic Phencyclidine Administration in Rats J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 831 - 837. [Abstract] [Full Text] |
||||